Objective: To assess variation in genes that regulate cholesterol metabolism in relation to the natural history of HIV infection.
Introduction
Cholesterol is used by animal cells to maintain the liquidsolid structure of plasma membranes necessary for cell signaling pathways and other essential functions. Cholesterol is also used by a variety of human pathogens, Mycobacterium tuberculosis, HIV, influenza, and hepatitis C virus (HCV), to support various aspects of their life cycles: membrane fusion and entry into cells, viral budding, immune evasion, and transport through the bloodstream [1] . Cholesterol use by HIV has been well studied. The HIV Nef protein stimulates cholesterol biosynthesis by HIV-infected cells and also inhibits activity of ATP binding cassette subfamily A member 1 (ABCA1) -a cellular cholesterol transporter -to reduce cholesterol efflux from cells [2] [3] [4] . Excess cellular cholesterol is directed to cholesterol-rich domains of the plasma membrane (lipid rafts) to support assembly and budding of HIV virions [3] [4] [5] .
Another role for cholesterol in the HIV lifecycle is to mediate transinfection of CD4 þ T cells by antigen presenting cells, a process that plays a role in sexually transmitted HIV [6] . Cholesterol is required for uptake of HIV by dendritic cells and subsequent transfer to CD4 þ T cells [7] , and a recent study demonstrated significantly lower levels of cholesterol in dendritic cells and B cells of HIV-infected (HIV þ ) nonprogressors when compared with HIV þ progressors [8] .
Many groups -including our own [9] -have sought to identify host genetic factors associated with HIV pathogenesis, as defined primarily by HIV viral load levels, CD4 þ T-cell levels, or time from HIV seroconversion to AIDS/death. Only two genetic regions have consistent associations with HIV pathogenesis in genome-wide association studies (GWAS) -the human leukocyte antigen (HLA) class I region and the chemokine (C-C motif) receptor 5 region [10] . GWAS can be underpowered to identify associations with moderate effect sizes. GWAS of HIV are additionally limited by small sample sizes (compared with general population samples) and by heavy reliance on European ancestry cohorts [10] , although there are exceptions [11] . Thus, there remains a place in HIV research for candidate gene studies where a strong rationale exists for interrogation of certain genes, as is the case for genes that regulate cellular cholesterol levels.
Herein, we present a study of 19 candidate genes with roles in cholesterol regulation in relation to two biomarkers of HIV pathogenesis (HIV viral load and CD4 þ T-cell levels) in a multiracial cohort of antiretroviral therapy (ART)-naive women. Our analyses utilized methods that account for correlations between genetic variants involved in a common pathway. Significant associations were interrogated using bioinformatics tools and followed up by statistical and experimental studies.
Methods

Study population
Characteristics of the Women's Interagency HIV Study (WIHS) population have been described previously [12] . Briefly, HIV þ and HIV-negative (HIV À ) women were recruited from similar risk settings at six US sites (Bronx, Brooklyn, Washington D.C., Chicago, San Francisco, and Los Angeles) during 1994-1995, 2001-2002, and 2011-2012 . Study visits (every 6 months) include a physical examination, collection of peripheral blood, and assessment of self-reported ART use (including querying participants about each antiretroviral agent) and other medications. This nested substudy was approved by the institutional review board of the Albert Einstein College of Medicine.
Single nucleotide polymorphism typing
Single nucleotide polymorphisms (SNPs) were genotyped using the Illumina HumanOmni2.5-quad beadchip (Illumina, San Diego, California, USA) for all WIHS women enrolled in 1994-1995 and 2001-2002 who provided consent for genetic testing (n ¼ 3353). Excluded from the dataset were SNPs with a genotype call rate of less than 95% and SNPs that failed our in-house quality control criteria. Specifically, SNPs with at least two discordant genotypes among greater than 20 duplicate samples were excluded. SNPs within and flanking (i.e. approximately 20 kb surrounding) 19 candidate cholesterol genes [ABCA1, ATP binding cassette subfamily G member 1 (ABCG1), ATP binding cassette subfamily A member 12 (ABCA12), scavenger receptor class B member 1 (SCARB1), lowdensity lipoprotein receptor, solute carrier family 10 member 2 (SLC10A2), tetratricopeptide repeat domain 39B (TTC39B), cytochrome P450 family 39 subfamily A member 1 (CYP39A1), cholesteryl ester transfer protein (CETP), proprotein convertase subtilisin/kexin type 9 (PCSK9), mevalonate kinase, retinoid X receptor alpha (RXRA), nuclear receptor subfamily 1 group H member 3 (NR1H3), nuclear receptor corepressor 1 (NCOR1), nuclear receptor corepressor 2 (NCOR2), sterol regulatory element binding transcription factor 1 (SREBF1), NR1H3, nuclear receptor subfamily 1 group H member 2 (NR1H2), and retinoid X receptor beta (RXRB)] were used. Ancestry informative marker SNPs from the Illumina beadchip were selected from across the genome using Helix Tree (Golden Helix, Bozeman, Montana, USA) to calculate principal components of genomic race/ethnicity.
Clinical laboratory measurements
Plasma HIV RNA levels were originally measured through WIHS visit 6 with a nucleic acid sequencebased amplification method that had 4000 copies/ml as its lower limit of quantification (LLQ -Organon Teknika Corp., Durham, North Carolina, USA). Similar methods with greater sensitivity were used thereafter as they became clinically available (the LLQ was 400 copies/ml during visits 7-9 and 80 copies/ml thereafter). There has been an effort to remeasure HIV RNA levels with more sensitive assays at WIHS visits where assay LLQ was 400 or 4000 copies/ml and the HIV viral load was at the LLQ. This effort succeeded for most visits but remeasurement of HIV RNA levels was not possible at visits with insufficient plasma in the WIHS repository. Total CD4 þ T-cell counts (cells/ml) were determined by flow cytometry in laboratories participating in the Division of AIDS Quality Assurance Program at each study visit [13] .
HCV serostatus was determined at enrollment (defined as WIHS visits 1-3 for hepatitis testing) using a commercial second or third-generation enzyme immunoassay, and HCV viremia was determined in HCV-seropositive women using either the COBAS Amplicor Monitor 2.0, which has a linear range of 600-5.0 Â 10 5 IU/ml, as previously described [14] , or the COBAS Taqman assay, which has a linear range of 10-2.0 Â 10 8 IU/ml (both from Roche Diagnostics, Branchburg, New Jersey, USA).
The WIHS initiated collection of fasting blood and cholesterol measurements in October 2000. Total cholesterol, high-density lipoprotein cholesterol (HDL-C) and triglycerides were measured on a Roche Modular automated system (Roche Diagnostics Corporation, Indianapolis, Indiana, USA). Low-density lipoprotein cholesterol (LDL-C) was calculated using the 
Genetic epidemiology methods
The study was restricted to HIV þ women who had at least one ART-naive study visit prior to 1 October 1996 -when prevalence of HAART use first exceeded 5% of WIHS study participants. The reason for not including ART-naive visits after this time was because of selective ARTuse among the sickest individuals [15] , which would have biased our investigation of polymorphisms with untreated HIV viral load. We used this same inclusion criterion in a prior study in which we observed well recognized associations of HLA-B Ã 57 : 01, B Ã 57 : 03, and other alleles with HIV viral load and CD4
þ T-cell levels [9] .
We examined SNPs within and flanking cholesterol genes in relation to two biomarkers: HIV viral load and CD4 þ T-cell levels. HIV viral load was log 10 transformed, whereas CD4
þ T-cell levels were square root transformed [9] . We used elastic net models implemented using the glmnet package in R [16] .
The elastic net considers all SNP and phenotype data simultaneously in a single high-dimensional model. The advantage of simultaneous analysis is that correlations and dependencies (multicollinearity) between SNPs are included. Elastic net models require specification of two tuning parameters: l 1 and l 2 . For l 2 we chose 0.5 as suggested by a recent study that evaluated penalized regression techniques using simulated and real data [17] . The value of l 1 was selected by controlling the false discovery rate (FDR) at three commonly used thresholds: 0.1, 0.05, and 0.01.
Because we had access to only a single dataset of ARTnaive HIV þ individuals, we conducted an internal replication step to decrease the likelihood of false positives. We only considered SNPs associated with both HIV viral load and CD4 þ T-cell levels to pass our internal replication criterion. HLA-B Ã 57 : 01 and B Ã 57 : 03 met this criterion in our prior WIHS study [9] . Nevertheless, our study provides only exploratory data related to host control of HIV. Definitive data (e.g. as generated by the International HIV Controllers Study [18] ) generally require much larger sample sizes, large replication cohorts, and in-vitro mechanistic studies to validate statistical observations.
Bioinformatics methods
We conducted bioinformatics analyses for associations identified under the most conservative FDR threshold (0.01) that met our internal replication criterion. The software programs were: RegulomeDB [19] , SNPInfo [20] , functional single nucleotide polymorphism (F-SNP) [21] , rSNPBase [22] , Haploreg v4.1 [23] , MicroSNiPer [24] , and miRNASNP [25] . Two programs were used to calculate microRNA binding energies: mrSNP [26] and MirSNP [27] .
Statistical methods
We confirmed elastic net SNP associations using linear regression and generalized estimating equation (GEE) models with exchangeable correlation structures. Longitudinal data analysis using GEE including multiple time-points/participant is a well established statistical technique, including in the WIHS cohort [28] . We chose a correlation structure based on comparison of goodnessof-fit statistics using the Quasi likelihood under the independence model criterion (QIC) [29] . We also examined associations stratified by HCV status, as HCV coinfection was common in the cohort and use of cholesterol in the HCV lifecycle is documented [1, 30] .
Finally, we determined associations with total cholesterol, HDL-C, and LDL-C using adjusted GEE models and stratified by HCV coinfection status. Only data from women contributing a fasting blood sample (self-report of not eating for at least 8 h) were included. Cholesterol analyses included adjustment for principal components of genomic race/ethnicity, age, and self-reported race/ ethnicity (to minimize confounding by population substructure) and also other factors known or hypothesized to affect cholesterol levels (to increase statistical power), as described in our prior WIHS study [31] . The major racial groups in WIHS (African ancestry, European ancestry and Amerindian ancestry) are easily discriminated based on the first two principal components [32] and adjustment for five principal components is generally sufficient to control for confounding by population substructure. Stratified analyses by self-reported race/ ethnicity reduces power and may not have the desired effect in heavily admixed populations such as WIHS where self-report often does not reflect actual ancestry and many participants self-report as 'other' race/ethnicity [32] .
Measurement of proprotein convertase subtilisin/kexin type 9 levels in plasma PCSK9 levels in plasma were measured by hPCSK9 ELISA (R&D Systems, Minneapolis, Minnesota, USA) according to manufacturer's protocol.
Results
Study population characteristics
The study included n ¼ 1066 HIV þ women, all of whom were ART naive at enrollment into WIHS and for whom genotype data for candidate cholesterol genes was available. WIHS women who: were HIV seronegative; reported any prior ART use (including ART monotherapy) at enrollment, were enrolled after 1996, or lacked genotype data were excluded from the analytic dataset. The majority of the studied n ¼ 1066 HIV þ women were African American and low income (Table 1 ). In total 32% of the cohort had a history of AIDS and 38% were HIV/HCV coinfected.
Because we used ART-naive HIV viral load and CD4 þ T-cell measurements prior to 1 October 1996 for the analyses (see methods), measurements from some women were taken from several follow-up visits. The distribution of contributed data were: 1 visit: n ¼ 325 women; 2 visits: n ¼ 246 women; 3 visits: n ¼ 295 women; 4 visits: n ¼ 187 women; 5 visits: n ¼ 13 women. In total, n ¼ 2515 HIV viral load measurements and n ¼ 2463 CD4 þ T-cell measurements were used for genetic analyses. Longitudinal data provide more information regarding genetic effects over time as compared with cross-sectional data.
Single nucleotide polymorphism associations with HIV viral load and CD4
R T-cell levels We considered 2050 SNPs within and flanking 19 candidate cholesterol genes using elastic net models with FDR thresholds of 0.1, 0.05, and 0.01. These models identified, respectively, 129, 78, and 43 SNPs significantly associated with HIV viral load and 120, 68, and 25 SNPs significantly associated with CD4 þ T-cell levels (Supplementary Table 1 , http://links.lww.com/QAD/B163). At FDR thresholds of 0.1, 0.05, and 0.01 -26, 14, and 6 SNPs, respectively, met our internal replication criterion (associated with both HIV viral load and CD4 þ T-cell levels - Supplementary Tables 1 and 2 , http://links. lww.com/QAD/B163). Elastic net models that included adjustment for age, self-reported race/ethnicity, and principal components of genomic race and ethnicity yielded identical results. We confirmed the absence of confounding by age, self-reported race/ethnicity, and principal components of genomic race/ethnicity by visually inspecting diagnostic plots (data not shown).
We used linear regression models to confirm SNP associations identified under the most conservative threshold (FDR ¼ 0.01) that met our internal replication criterion ( Table 2) . Five of six SNPs identified by elastic net had significant associations in linear regression. The only SNP not associated with HIV viral load or CD4 þ T-cell levels in linear regression analysis was rs11610540 (Table 2) .
Bioinformatics evaluation of significant single nucleotide polymorphisms Bioinformatics programs yielded largely conflicting findings regarding potential functional effects of six SNPs identified under the most conservative FDR threshold that met our internal replication criterion (Table 3) . However, three bioinformatics programs identified differences in microRNA binding by alleles of rs17111557 -located in the 3 0 untranslated region (UTR) of PCSK9 -as a putative effect of this SNP (Table  3) . A PubMed search on these six SNPs yielded no results for five, and only a search for rs17111557 located a peerreviewed publication [33] . We used two bioinformatics programs (mrSNP [26] and MirSNP [27] ) to calculate microRNA binding energies. Both programs predict binding energy differences for hsa-miR-548t-5p and hsamiR-4796-3p for individuals with different alleles of rs17111557 (Supplementary Tables 3 and 4 þ T-cell levels (b: À2.0; 95% CI: À3.5, À0.5; P ¼ 0.008). In these GEE models rs17111557 was considered with adjustment for age (linear term), self-reported race/ethnicity, and the first five principal components of genomic race/ethnicity. Because 38% of the cohort was HIV/HCV coinfected, and use of cholesterol in the HCV lifecycle is documented [1, 30] , we stratified by HCV status. In n ¼ 638 women with HCV RNA negative status, associations of rs17111557, adjusted for age, self-reported race/ethnicity, and the first five principal components of genomic race/ethnicity, with HIV viral load (b: 0.2; 95% CI: À0.1, 0.4; P ¼ 0.19) and CD4 þ T-cell levels (b:À1.3; 95% CI: À3.2, 0.6; P ¼ 0.17) were not statistically significant. In contrast, in n ¼ 405 HIV/HCV coinfected women adjusted associations of rs17111557 with HIV viral load (b: 0.44; 95% CI: 0.2, 0.7; P < 0.001) and CD4 þ T-cell levels (b:À3.0; 95% CI: À5.3, À0.6; P ¼ 0.01) were statistically significant and stronger than in the total study population. Additional adjustment for Proprotein convertase subtilisin/kexin type 9 Kuniholm et al. 2487 Table 2 . Single-nucleotide polymorphisms identified in elastic net models with false discovery rate equal to 0.01 that met our internal replication criterion a . log 10 HCV viral load (measured at the WIHS enrollment visit) did not affect associations of rs17111557 with HIV viral load and CD4 þ T-cell levels in HIV/HCV coinfected women (data not shown). Rs17111557 was not significantly associated with log 10 HCV viral load in HIV/HCV coinfected women in analysis adjusted for age, self-reported race/ethnicity, and the first five principal components of genomic race/ethnicity (b: 0.2; 95% CI: 0.0, 0.5; P ¼ 0.06).
HIV viral load
To better understand the mechanism(s) through which rs17111557 might affect HIV, we determined associations with total cholesterol, HDL-C, and LDL-C measurements using adjusted GEE models. Cholesterol was measured on an annual basis for most WIHS women starting in the year 2000, therefore, the 1994-1996 ART-naive HIV viral load and CD4
þ T-cell data are not contemporaneous with cholesterol measurements. The analysis was restricted to the subset of the total study population (see Table 1 ) who remained enrolled in the WIHS cohort through the year 2000 and had at least one LDL-C measurement.
No significant associations of rs17111557 with total cholesterol or HDL-C were observed for HIV monoinfected or HIV/HCV coinfected women (data not shown). In contrast, we observed a significant association of rs17111557 with LDL-C levels in HIV/HCV coinfected women (n ¼ 205; 1533 LDL-C measurements; b: À10.4; 95% CI: À17.9, À2.9; P ¼ 0.007) but not in HIV monoinfected women (n ¼ 437; 4187 LDL-C measurements; b: 1.2; 95% CI: À6.3, 8.6; P ¼ 0.76) in analyses adjusted for age, self-reported race/ethnicity, the first five principal components of genomic race and ethnicity, and other factors known or hypothesized to affect cholesterol levels in HIV/HCV coinfected women (Table 4) . Nelfinavir use was significantly associated with higher LDL-C levels in both HIV monoinfected and HIV/HCV coinfected women (Table 4 ). In contrast, lamivudine (3TC) use and the number of protease inhibitors were significantly associated with higher LDL-C levels only in HIV monoinfected women (Table 4) .
Plasma levels of proprotein convertase subtilisin/ kexin type 9 in African American HIV/hepatitis C virus coinfected women To clarify associations of PCSK9 pathways with HIV/ HCV, we measured PCSK9 in plasma from the subset of HIV/HCV coinfected women who were African American (n ¼ 249), to minimize confounding by racial/ ethnic differences in PCSK9 levels. One measurement was excluded because of technical issues. In total, 45% (n ¼ 112) of women had an ART-naive plasma sample prior to 1 October 1996 available for PCSK9 measurement; for those women without a plasma sample prior to 1 October 1996 (n ¼ 136) we selected the first time point at which fasting blood was collected (Supplementary http://links.lww.com/QAD/B162). Additional adjustment for rs17111557 did not change this association (data not shown). Plasma PCSK9 levels were not associated with contemporaneous LDL-C (Supplementary Figure 6 , http://links.lww.com/QAD/B162) or HDL-C in bivariate analyses and additional adjustment for age, five principal components of genomic race/ethnicity, current smoking, education, income, IDU at baseline, receipt of ART, and rs17111557 did not change these null associations (data not shown).
Discussion
The study -conducted in a historical US cohort of ARTnaive HIV þ women -found that a 3 0 UTR variant of Proprotein convertase subtilisin/kexin type 9 Kuniholm et al. 2489 The analysis was restricted to the subset of the total study population (see Table 1 ) who remained enrolled in the WIHS cohort through the year 2000 and had at least one LDL-C measurement.
d FIB-4 is a noninvasive marker of liver fibrosis, as defined in [34] .
e Use of lipid lowering agents was self-reported: Lescol (fluvastatin), Lipitor (atorvastatin), Mevacor, Altocor (lovastatin), Pravachol (pravastatin), Zocor (simvastatin), Crestor (rosuvastatin), Lopid (gemfibrozil), TriCor (fenofibrate), Colestid (colestipol), Questran (cholestyramine), Welchol (colesevelam), Niaspan (niacin), Zetia (ezetimibe), Caduet (amlodipine and atorvastatin), Vytorin (ezetimibe and simvastatin), Advicor (lovastatin and niacin), Pravigard (pravastatin and buffered aspirin), or Omacor.
f Antiretroviral therapies significantly associated with LDL-C levels in our prior study of HIV þ WIHS women [31] were included in the analysis.
PCSK9 (rs17111557) is associated with biomarkers of HIV pathogenesis and lipid homeostasis in HIV/HCV coinfected women. Differential binding of hsa-miR548t-5p and hsa-miR-4796-3p to the PCSK9 3 0 UTR in individuals with different alleles of rs17111557 could represent the mechanism through which rs17111557 affects LDL-C, HIV viral load, and CD4 þ T-cell levels. These associations, if replicated, are important because they link PCSK9, a gene of clinical and therapeutic importance in the general population, with specific aspects of HIV pathogenesis in HIV/HCV coinfected women.
Genetic variants in or near NCOR2 (silencing mediator of retinoic acid and thyroid hormone receptor), RXRA, and TTC39B may also be associated with biomarkers of HIV pathogenesis in WIHS women. However, these SNPs were localized in the introns and our evaluation of these variants using bioinformatics tools yielded conflicting findings. Therefore, we focused on rs17111557 -a putatively functional SNP. Nevertheless, we note that three of the top six SNPs identified in our analyses were in NCOR2. NCOR2 is a member of the nuclear corepressor family of histone deacetylases, which are components of the transcription silencing machinery, and SNPs in NCOR2 were found to significantly associate with HIV acquisition [35] .
It is not surprising that rs17111557 has not previously been identified as a correlate of HIV pathogenesis. There is little global variation in rs17111557 except in African ancestry populations -for example, in the CEU (Utah Residents with Northern and Western European Ancestry) HapMap population allele frequencies at this locus are 99% C and 1% T. Many if not all genetic studies of HIV have been conducted in European ancestry cohorts [10, 11] .
PCSK9 plays a central role in lipid homeostasis by enhancing degradation of hepatic low-density lipoprotein receptor, resulting in increased serum LDL-C [36] . PCSK9 is also expressed in extra-hepatic tissues (e.g. small intestine) where it can affect vascular biology through LDL-dependent and/or LDL-independent mechanisms, including mechanisms that regulate inflammation, blood pressure, and glucose homeostasis [37, 38] . PCSK9 also downregulates CD81 and very-low-density lipoprotein receptors on hepatocytes [39, 40] . CD81 and very-lowdensity lipoprotein receptors are used by HCV to gain entry into cells [41] and PCSK9 levels modulate HCV infectivity in vitro [40] . The role of PCSK9 in inflammation, immunologic processes, and infection is an area of active investigation [42, 43] . Surprisingly, despite higher median levels of plasma PCSK9 in HIV/HCV coinfected women with rs17111557 TC vs. CC genotype, no significant association of rs17111557 was observed. This finding suggests that rs17111557 may exert only a modest effect on plasma PCSK9 levels, and a larger sample size could show statistical significance. It is also possible that 3 0 UTR polymorphism in PCSK9 may alter temporal regulation of PCSK9 expression, or it may affect PCSK9 expression only in certain cell populations (e.g. those expressing high levels of hsa-miR-548t-5p and hsa-miR-4796-3p). It is also possible that rs17111557 affects lipid and viral load levels through PCSK9-independent mechanisms, such as altering the levels of inflammatory cytokines or other pathways [44] . Both plasma PCSK9 and interleukin (IL)-6 levels were elevated in HIV/HCV coinfected as compared to HIV monoinfected patients in a majority male White population [45] .
In addition to rs17111557, several associations with LDL-C were observed in multivariate analyses. Particularly striking was the inverse association between age and LDL-C levels in HCV/HIV coinfected women. These data are consistent with those of a study that showed progressive declines of LDL-C over time among HCV monoinfected veterans with known dates of HCV seroconversion [46] . The association of older age with lower LDL-C in that study was independent of FIB-4, a marker of liver fibrosis [34] , as was observed in WIHS women. Use of lipid lowering medications was inversely associated with LDL-C levels in both HCV/HIV coinfected and HIV monoinfected women, highlighting the effectiveness of these medications despite dysregulated lipid homeostasis. Furthermore, a recent study observed that statin use was associated with lower incidence of liver cirrhosis and hepatocellular carcinoma in HCV þ veterans [47] . A future research priority will, therefore, be to define effects of recently approved PCSK9 inhibitorswhich have favorable toxicity and drug-drug interaction profiles as compared to statins -in HIV monoinfected and HCV/HIV coinfected women.
Limitations must be considered in the interpretation of these data. First, WIHS did not collect fasting blood or measure lipids during the pre-HAART era (1994) (1995) (1996) . Second, we identified a SNP in the seed of hsa-miR548t-5p (rs73872515) with variation in African ancestry populations but were unable to test this SNP for epistatic interaction with rs17111557 because it was not available in WIHS. Third, our study only included women. Plasma PCSK9 levels were significantly higher in women as compared to men in a large (n ¼ 3138) ethnically diverse US population, and sex differences persisted after adjustment for age, ethnicity, BMI, SBP, menopausal status, and fasting levels of glucose, LDL-C, HDL-C, triglycerides, and c-reactive protein [48] . Thus, it is possible that interactions of HIV, HCV, and PCSK9 also differ by sex. Fourth, the primary phenotypes considered in our study were HIV viral load and CD4 þ T-cell levels, but other phenotypes not considered under the current investigation may also be important. For example, recent studies in the general population have considered host variation at PCSK9 and 3-hydroxy-3-methyl-glutarylcoenzyme A reductase (HMGCR; the target of statins) loci in relation to cardiovascular disease and cognitive function phenotypes [49, 50] . The relation of cholesterol pathway gene variation in relation to other HCV-related phenotypes such as spontaneous HCV clearance and liver disease progression may also warrant further investigation. Fifth, unlike some cohorts (e.g. the Multicenter AIDS Cohort Study), the WIHS did not have a long period in the pre-HAARTera and thus our capacity to study CD4 þ decline in WIHS or clinical outcomes associated with untreated HIV infection is limited. Finally, associations of rs17111557 need to be replicated. Nevertheless, we report the discovery of these associations because rs17111557 was associated with multiple distinct phenotypes in WIHS women, has supporting bioinformatics data, and is potentially of interest to HIV and/or HCV clinicians considering use of PCSK9 inhibitors in their patients. Cholesterol plays a critically important role in the lifecycle of HIV and HCV. Candidate gene study designs may provide useful insights regarding which specific cholesterol-related pathways may be targeted for the development of new strategies to prevent or control HIV and other human pathogens.
